S6K2: The neglected S6 kinase family member

Frontiers in Oncology

Volumn 3 JUL, Issue , 2013, Pages

  Pardo, Olivier E ^a   Seckl, Michael J ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Cancer; Function; RPS6KB2; S6 kinase; S6K2; Selectivity; Specificity

Indexed keywords

ADENOSINE TRIPHOSPHATE; FIBROBLAST GROWTH FACTOR RECEPTOR 1; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; PHOSPHATIDATE PHOSPHATASE; PROTEIN SERINE THREONINE KINASE; S6 KINASE 2; UNCLASSIFIED DRUG;

ALLOSTERISM; AMINO ACID SEQUENCE; BIOLOGICAL ACTIVITY; CARCINOGENESIS; CELL CYCLE REGULATION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CHROMOSOME 11; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; NEOPLASM; NONHUMAN; PHYSIOLOGICAL PROCESS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; PROTEIN TRANSLATION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

EID: 84891047861     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00191     Document Type: Review

References (111)

1. Anjum R, Blenis J. The RSK family of kinases: emerging roles in cellular signalling. Nat Rev Mol Cell Biol (2008) 9:747-58. doi:10.1038/nrm2509
2. Jeno P, Ballou LM, Novak-Hofer I, Thomas G. Identification and characterization of a mitogen-activated S6 kinase. Proc Natl Acad Sci U S A (1988) 85:406-10.
3. Nemenoff RA, Price DJ, Mendelsohn MJ, Carter EA, Avruch J. An S6 kinase activated during liver regeneration is related to the insulin-stimulated S6 kinase in H4 hepatoma cells. J Biol Chem (1988) 263:19455-60.
4. Gout I, Minami T, Hara K, Tsujishita Y, Filonenko V, Waterfield MD, et al. Molecular cloning and characterization of a novel p70 S6 kinase, p70 S6 kinase beta containing a proline-rich region. J Biol Chem (1998) 273:30061-4.
5. Saitoh M, Ten Dijke P, Miyazono K, Ichijo H. Cloning and characterization of p70(S6K beta) defines a novel family of p70 S6 kinases. Biochem Biophys Res Commun (1998) 253:470-6. doi:10.1006/bbrc.1998.9784
6. Lee-Fruman KK, Kuo CJ, Lippincott J, Terada N, Blenis J. Characterization of S6K2, a novel kinase homologous to S6K1. Oncogene (1999) 18:5108-14.
7. Fenton TR, Gout IT. Functions and regulation of the 70kDa ribosomal S6 kinases. Int J Biochem Cell Biol (2011) 43:47-59. doi:10.1016/j.biocel.2010.09.018
8. Magnuson B, Ekim B, Fingar DC. Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. Biochem J (2012) 441:1-21. doi:10.1042/BJ20110892
9. Savinska L, Skorokhod O, Klipa O, Gout I, Filonenko V. Development of monoclonal antibodies specific to ribosomal protein S6 kinase 2. Hybridoma (Larchmt) (2012) 31:289-94. doi:10.1089/hyb.2012.0032
10. Koh H, Jee K, Lee B, Kim J, Kim D, Yun YH, et al. Cloning and characterization of a nuclear S6 kinase, S6 kinase-related kinase (SRK); a novel nuclear target of Akt. Oncogene (1999) 18:5115-9.
11. Karni R, De Stanchina E, Lowe SW, Sinha R, Mu D, Krainer AR. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol (2007) 14:185-93.
12. Ben-Hur V, Denichenko P, Siegfried Z, Maimon A, Krainer A, Davidson B, et al. S6K1 alternative splicing modulates its oncogenic activity and regulates mTORC1. Cell Rep (2013) 3:103-15. doi:10.1016/j.celrep.2012.11.020
13. Pardo OE, Arcaro A, Salerno G, Tetley TD, Valovka T, Gout I, et al. Novel cross talk between MEK and S6K2 in FGF-2 induced proliferation of SCLC cells. Oncogene (2001) 20:7658-67.
14. Wang L, Gout I, Proud CG. Cross-talk between the ERK and p70 S6 kinase (S6K) signaling pathways. MEK-dependent activation of S6K2 in cardiomyocytes. J Biol Chem (2001) 276:32670-7. doi:10.1074/jbc.M102776200
15. Martin KA, Schalm SS, Richardson C, Romanelli A, Keon KL, Blenis J. Regulation of ribosomal S6 kinase 2 by effectors of the phosphoinositide 3-kinase pathway. J Biol Chem (2001) 276:7884-91.
16. Martin KA, Schalm SS, Romanelli A, Keon KL, Blenis J. Ribosomal S6 kinase 2 inhibition by a potent C-terminal repressor domain is relieved by mitogen-activated protein-extracellular signal-regulated kinase kinase-regulated phosphorylation. J Biol Chem (2001) 276:7892-8.
17. Phin S, Kupferwasser D, Lam J, Lee-Fruman KK. Mutational analysis of ribosomal S6 kinase 2 shows differential regulation of its kinase activity from that of ribosomal S6 kinase 1. Biochem J (2003) 373:583-91.
18. Schalm SS, Blenis J. Identification of a conserved motif required for mTOR signaling. Curr Biol (2002) 12:632-9. doi:10.1016/S0960-9822(02)00762-5
19. Nojima H, Tokunaga C, Eguchi S, Oshiro N, Hidayat S, Yoshino K, et al. The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J Biol Chem (2003) 278:15461-4.
20. Park IH, Bachmann R, Shirazi H, Chen J. Regulation of ribosomal S6 kinase 2 by mammalian target of rapamycin. J Biol Chem (2002) 277:31423-9.
21. Talvas J, Obled A, Fafournoux P, Mordier S. Regulation of protein synthesis by leucine starvation involves distinct mechanisms in mouse C2C12 myoblasts and myotubes. J Nutr (2006) 136:1466-71.
22. Shima H, Pende M, Chen Y, Fumagalli S, Thomas G, Kozma SC. Disruption of the p70(s6k)/p85(s6k) gene reveals a small mouse phenotype and a new functional S6 kinase. EMBO J (1998) 17:6649-59. doi:10.1093/emboj/17.22.6649
23. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem (2009) 284:8023-32. doi:10.1074/jbc.M900301200
24. Moorman NJ, Shenk T. Rapamycin-resistant mTORC1 kinase activity is required for herpesvirus replication. J Virol (2010) 84:5260-9. doi:10.1128/JVI.02733-09
25. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol (2009) 7::e38. doi:10.1371/journal.pbio.1000038
26. Valovka T, Verdier F, Cramer R, Zhyvoloup A, Fenton T, Rebholz H, et al. Protein kinase C phosphorylates ribosomal protein S6 kinase betaII and regulates its subcellular localization. Mol Cell Biol (2003) 23:852-63. doi:10.1128/MCB.23.3.852-863.2003
27. Rebholz H, Panasyuk G, Fenton T, Nemazanyy I, Valovka T, Flajolet M, et al. Receptor association and tyrosine phosphorylation of S6 kinases. FEBS J (2006) 273:2023-36.
28. Wang ML, Panasyuk G, Gwalter J, Nemazanyy I, Fenton T, Filonenko V, et al. Regulation of ribosomal protein S6 kinases by ubiquitination. Biochem Biophys Res Commun (2008) 369:382-7. doi:10.1016/j.bbrc.2008.02.032
29. Gwalter J, Wang ML, Gout I. The ubiquitination of ribosomal S6 kinases is independent from the mitogen-induced phosphorylation/activation of the kinase. Int J Biochem Cell Biol (2009) 41:828-33.
30. Fenton TR, Gwalter J, Ericsson J, Gout IT. Histone acetyltransferases interact with and acetylate p70 ribosomal S6 kinases in vitro and in vivo. Int J Biochem Cell Biol (2010) 42:359-66. doi:10.1016/j.biocel.2009.11.022
31. Panasyuk G, Nemazanyy I, Filonenko V, Gout I. Ribosomal protein S6 kinase 1 interacts with and is ubiquitinated by ubiquitin ligase ROC1. Biochem Biophys Res Commun (2008) 369:339-43. doi:10.1016/j.bbrc.2008.02.016
32. Xiao XS, Cai MY, Chen JW, Guan XY, Kung HF, Zeng YX, et al. High expression of p300 in human breast cancer correlates with tumor recurrence and predicts adverse prognosis. Chin J Cancer Res (2011) 23:201-7. doi:10.1007/s11670-011-0201-5
33. Hou X, Li Y, Luo RZ, Fu JH, He JH, Zhang LJ, et al. High expression of the transcriptional co-activator p300 predicts poor survival in resectable non-small cell lung cancers. Eur J Surg Oncol (2012) 38:523-30.
34. Liao ZW, Zhou TC, Tan XJ, Song XL, Liu Y, Shi XY, et al. High expression of p300 is linked to aggressive features and poor prognosis of nasopharyngeal carcinoma. J Transl Med (2012) 10::110. doi:10.1186/1479-5876-10-110
35. Li Y, Yang HX, Luo RZ, Zhang Y, Li M, Wang X, et al. High expression of p300 has an unfavorable impact on survival in resectable esophageal squamous cell carcinoma. Ann Thorac Surg (2011) 91:1531-8. doi:10.1016/j.athoracsur.2010.12.012
36. Yokomizo C, Yamaguchi K, Itoh Y, Nishimura T, Umemura A, Minami M, et al. High expression of p300 in HCC predicts shortened overall survival in association with enhanced epithelial mesenchymal transition of HCC cells. Cancer Lett (2011) 310:140-7. doi:10.1016/j.canlet.2011.06.030
37. Hirano G, Izumi H, Kidani A, Yasuniwa Y, Han B, Kusaba H, et al. Enhanced expression of PCAF endows apoptosis resistance in cisplatin-resistant cells. Mol Cancer Res (2010) 8:864-72. doi:10.1158/1541-7786.MCR-09-0458
38. Shiota M, Yokomizo A, Tada Y, Uchiumi T, Inokuchi J, Tatsugami K, et al. P300/CBP-associated factor regulates Y-box binding protein-1 expression and promotes cancer cell growth, cancer invasion and drug resistance. Cancer Sci (2010) 101:1797-806. doi:10.1111/j.1349-7006.2010.01598.x
39. Toth M, Boros IM, Balint E. Elevated level of lysine 9-acetylated histone H3 at the MDR1 promoter in multidrug-resistant cells. Cancer Sci (2012) 103:659-69. doi:10.1111/j.1349-7006.2012.02215.x
40. Rossi R, Pester JM, Mcdowell M, Soza S, Montecucco A, Lee-Fruman KK. Identification of S6K2 as a centrosome-located kinase. FEBS Lett (2007) 581:4058-64.
41. Nardella C, Lunardi A, Fedele G, Clohessy JG, Alimonti A, Kozma SC, et al. Differential expression of S6K2 dictates tissue-specific requirement for S6K1 in mediating aberrant mTORC1 signaling and tumorigenesis. Cancer Res (2011) 71:3669-75.
42. Pardo OE, Wellbrock C, Khanzada UK, Aubert M, Arozarena I, Davidson S, et al. FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2. EMBO J (2006) 25:3078-88.
43. Filonenko VV, Tytarenko R, Azatjan SK, Savinska LO, Gaydar YA, Gout IT, et al. Immunohistochemical analysis of S6K1 and S6K2 localization in human breast tumors. Exp Oncol (2004) 26:294-9.
44. Lyzogubov VV, Lytvyn DI, Dudchenko TM, Lubchenko NV, Pogrybniy PV, Nespryadko SV, et al. Immunohistochemical analysis of S6K1 and S6K2 expression in endometrial adenocarcinomas. Exp Oncol (2004) 26:287-93.
45. Perez-Tenorio G, Karlsson E, Waltersson MA, Olsson B, Holmlund B, Nordenskjold B, et al. Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer. Breast Cancer Res Treat (2011) 128:713-23. doi:10.1007/s10549-010-1058-x
46. Lyzogubov V, Khozhaenko Y, Usenko V, Antonjuk S, Ovcharenko G, Tikhonkova I, et al. Immunohistochemical analysis of Ki-67, PCNA and S6K1/2 expression in human breast cancer. Exp Oncol (2005) 27:141-4.
47. Pende M, Um SH, Mieulet V, Sticker M, Goss VL, Mestan J, et al. S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5'-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Mol Cell Biol (2004) 24:3112-24.
48. Ruvinsky I, Katz M, Dreazen A, Gielchinsky Y, Saada A, Freedman N, et al. Mice deficient in ribosomal protein S6 phosphorylation suffer from muscle weakness that reflects a growth defect and energy deficit. PLoS One (2009) 4::e5618. doi:10.1371/journal.pone.0005618
49. Dibble CC, Asara JM, Manning BD. Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Mol Cell Biol (2009) 29:5657-70. doi:10.1128/MCB.00735-09
50. Karlsson E, Waltersson MA, Bostner J, Perez-Tenorio G, Olsson B, Hallbeck AL, et al. High-resolution genomic analysis of the 11q13 amplicon in breast cancers identifies synergy with 8p12 amplification, involving the mTOR targets S6K2 and 4EBP1. Genes Chromosomes Cancer (2011) 50:775-87. doi:10.1002/gcc.20900
51. Wang L, Rhodes CJ, Lawrence JC Jr. Activation of mammalian target of rapamycin (mTOR) by insulin is associated with stimulation of 4EBP1 binding to dimeric mTOR complex 1. J Biol Chem (2006) 281:24293-303. doi:10.1074/jbc.M603566200
52. Yoshida S, Matsumoto K, Arao T, Taniguchi H, Goto I, Hanafusa T, et al. Gene amplification of ribosomal protein S6 kinase-1 and-2 in gastric cancer. Anticancer Res (2013) 33:469-75.
53. Vazquez-Higuera JL, Mateo I, Sanchez-Juan P, Rodriguez-Rodriguez E, Pozueta A, Calero M, et al. Genetic variation in the tau kinases pathway may modify the risk and age at onset of Alzheimer's disease. J Alzheimers Dis (2011) 27:291-7. doi:10.3233/JAD-2011-110794
54. Slattery ML, Lundgreen A, Herrick JS, Wolff RK. Genetic variation in RPS6KA1, RPS6KA2, RPS6KB1, RPS6KB2, and PDK1 and risk of colon or rectal cancer. Mutat Res (2011) 706:13-20. doi:10.1016/j.mrfmmm.2010.10.005
55. Kim JH, Shin SH, Kwon HJ, Cho NY, Kang GH. Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers. Virchows Arch (2009) 455:485-94. doi:10.1007/s00428-009-0857-0
56. Bae JM, Kim MJ, Kim JH, Koh JM, Cho NY, Kim TY, et al. Differential clinicopathological features in microsatellite instability-positive colorectal cancers depending on CIMP status. Virchows Arch (2011) 459:55-63. doi:10.1007/s00428-011-1080-3
57. Van Rijnsoever M, Elsaleh H, Joseph D, Mccaul K, Iacopetta B. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin Cancer Res (2003) 9:2898-903.
58. Iacopetta B, Kawakami K, Watanabe T. Predicting clinical outcome of 5-fluorouracil-based chemotherapy for colon cancer patients: is the CpG island methylator phenotype the 5-fluorouracil-responsive subgroup? Int J Clin Oncol (2008) 13:498-503. doi:10.1007/s10147-008-0854-3
59. Fingar DC, Salama S, Tsou C, Harlow E, Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev (2002) 16:1472-87. doi:10.1101/gad.995802
60. Chauvin C, Koka V, Nouschi A, Mieulet V, Hoareau-Aveilla C, Dreazen A, et al. Ribosomal protein S6 kinase activity controls the ribosome biogenesis transcriptional program. Oncogene (2013). [Epub ahead of print]. doi:10.1038/onc.2012.606
61. Ismail HM, Myronova O, Tsuchiya Y, Niewiarowski A, Tsaneva I, Gout I. Identification of the general transcription factor Yin Yang 1 as a novel and specific binding partner for S6 Kinase 2. Cell Signal (2013) 25:1054-63. doi:10.1016/j.cellsig.2013.02.002
62. Kurebayashi Y, Nagai S, Ikejiri A, Ohtani M, Ichiyama K, Baba Y, et al. PI3K-Akt-mTORC1-S6K1/2 axis controls Th17 differentiation by regulating Gfi1 expression and nuclear translocation of RORgamma. Cell Rep (2012) 1:360-73. doi:10.1016/j.celrep.2012.02.007
63. Ruvinsky I, Sharon N, Lerer T, Cohen H, Stolovich-Rain M, Nir T, et al. Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. Genes Dev (2005) 19:2199-211.
64. Patursky-Polischuk I, Stolovich-Rain M, Hausner-Hanochi M, Kasir J, Cybulski N, Avruch J, et al. The TSC-mTOR pathway mediates translational activation of TOP mRNAs by insulin largely in a raptor-or rictor-independent manner. Mol Cell Biol (2009) 29:640-9. doi:10.1128/MCB.00980-08
65. Ferrari S, Bandi HR, Hofsteenge J, Bussian BM, Thomas G. Mitogen-activated 70K S6 kinase. Identification of in vitro 40 S ribosomal S6 phosphorylation sites. J Biol Chem (1991) 266:22770-5.
66. Meyuhas O. Physiological roles of ribosomal protein S6: one of its kind. Int Rev Cell Mol Biol (2008) 268:1-37.
67. Fitzgerald KD, Semler BL. Bridging IRES elements in mRNAs to the eukaryotic translation apparatus. Biochim Biophys Acta (2009) 1789:518-28. doi:10.1016/j.bbagrm.2009.07.004
68. Komar AA, Hatzoglou M. Cellular IRES-mediated translation: the war of ITAFs in pathophysiological states. Cell Cycle (2011) 10:229-40.
69. Liwak U, Thakor N, Jordan LE, Roy R, Lewis SM, Pardo O, et al. Tumour suppressor PDCD4 represses IRES-mediated translation of anti-apoptotic proteins and is regulated by S6 kinase 2. Mol Cell Biol (2012) 32(10):1818-29. doi:10.1128/MCB.06317-11
70. Boyer D, Quintanilla R, Lee-Fruman KK. Regulation of catalytic activity of S6 kinase 2 during cell cycle. Mol Cell Biochem (2008) 307:59-64. doi:10.1007/s11010-007-9584-5
71. Cruz R, Hedden L, Boyer D, Kharas MG, Fruman DA, Lee-Fruman KK. S6 kinase 2 potentiates interleukin-3-driven cell proliferation. J Leukoc Biol (2005) 78:1378-85. doi:10.1189/jlb.0405225
72. Goh ET, Pardo OE, Michael N, Niewiarowski A, Totty N, Volkova D, et al. Involvement of heterogeneous ribonucleoprotein F in the regulation of cell proliferation via the mammalian target of rapamycin/S6 kinase 2 pathway. J Biol Chem (2010) 285:17065-76. doi:10.1074/jbc.M109.078782
73. Fujimoto K, Ichimori Y, Kakizoe T, Okajima E, Sakamoto H, Sugimura T, et al. Increased serum levels of basic fibroblast growth factor in patients with renal cell carcinoma. Biochem Biophys Res Commun (1991) 180:386-92.
74. Linder C, Linder S, Munck W, Strander H. Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma. Anticancer Res (1998) 18:2063-8.
75. Graeven U, Andre N, Achilles E, Zornig C, Schmiegel W. Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma. J Cancer Res Clin Oncol (1999) 125:577-81.
76. Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma. Blood (1999) 94:3334-9.
77. Joensuu H, Anttonen A, Eriksson M, Makitaro R, Alfthan H, Kinnula V, et al. Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer. Cancer Res (2002) 62:5210-7.
78. Ruotsalainen T, Joensuu H, Mattson K, Salven P. High pretreatment serum concentration of basic fibroblast growth factor is a predictor of poor prognosis in small cell lung cancer. Cancer Epidemiol Biomarkers Prev (2002) 11:1492-5.
79. Pardo OE, Arcaro A, Salerno G, Raguz S, Downward J, Seckl MJ. Fibroblast growth factor-2 induces translational regulation of Bcl-XL and Bcl-2 via a MEK-dependent pathway: correlation with resistance to etoposide-induced apoptosis. J Biol Chem (2002) 277:12040-6.
80. Pardo OE, Lesay A, Arcaro A, Lopes R, Ng BL, Warne PH, et al. Fibroblast growth factor 2-mediated translational control of IAPs blocks mitochondrial release of Smac/DIABLO and apoptosis in small cell lung cancer cells. Mol Cell Biol (2003) 23:7600-10.
81. Garneau D, Revil T, Fisette JF, Chabot B. Heterogeneous nuclear ribonucleoprotein F/H proteins modulate the alternative splicing of the apoptotic mediator Bcl-x. J Biol Chem (2005) 280:22641-50. doi:10.1074/jbc.M501070200
82. Carmo CR, Lyons-Lewis J, Seckl MJ, Costa-Pereira AP. A novel requirement for Janus kinases as mediators of drug resistance induced by fibroblast growth factor-2 in human cancer cells. PLoS One (2011) 6::e19861. doi:10.1371/journal.pone.0019861
83. He Z, Bateman A. Progranulin (granulin-epithelin precursor, PC-cell-derived growth factor, acrogranin) mediates tissue repair and tumorigenesis. J Mol Med (2003) 81:600-12.
84. Yin F, Banerjee R, Thomas B, Zhou P, Qian L, Jia T, et al. Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. J Exp Med (2010) 207:117-28. doi:10.1084/jem.20091568
85. Tapia L, Milnerwood A, Guo A, Mills F, Yoshida E, Vasuta C, et al. Progranulin deficiency decreases gross neural connectivity but enhances transmission at individual synapses. J Neurosci (2011) 31:11126-32. doi:10.1523/JNEUROSCI.6244-10.2011
86. Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature (2006) 442:916-9. doi:10.1038/nature05016
87. Almeida S, Zhang Z, Coppola G, Mao W, Futai K, Karydas A, et al. Induced pluripotent stem cell models of progranulin-deficient frontotemporal dementia uncover specific reversible neuronal defects. Cell Rep (2012) 2:789-98. doi:10.1016/j.celrep.2012.09.007
88. Koo DH, Park CY, Lee ES, Ro J, Oh SW. Progranulin as a prognostic biomarker for breast cancer recurrence in patients who had hormone receptor-positive tumors: a cohort study. PLoS One (2012) 7::e39880. doi:10.1371/journal.pone.0039880
89. Antion MD, Merhav M, Hoeffer CA, Reis G, Kozma SC, Thomas G, et al. Removal of S6K1 and S6K2 leads to divergent alterations in learning, memory, and synaptic plasticity. Learn Mem (2008) 15:29-38. doi:10.1101/lm.661908
90. Montagne J, Stewart MJ, Stocker H, Hafen E, Kozma SC, Thomas G. Drosophila S6 kinase: a regulator of cell size. Science (1999) 285:2126-9.
91. Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol (2004) 166:213-23. doi:10.1083/jcb.200403069
92. Zick Y. Uncoupling insulin signalling by serine/threonine phosphorylation: a molecular basis for insulin resistance. Biochem Soc Trans (2004) 32:812-6. doi:10.1042/BST0320812
93. Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M, et al. Absence of S6K1 protects against age-and diet-induced obesity while enhancing insulin sensitivity. Nature (2004) 431:200-5.
94. Julien LA, Carriere A, Moreau J, Roux PP. mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Mol Cell Biol (2010) 30:908-21.
95. Treins C, Warne PH, Magnuson MA, Pende M, Downward J. Rictor is a novel target of p70 S6 kinase-1. Oncogene (2010) 29:1003-16. doi:10.1038/onc.2009.401
96. Sheppard K, Kinross KM, Solomon B, Pearson RB, Phillips WA. Targeting PI3 kinase/AKT/mTOR signaling in cancer. Crit Rev Oncog (2012) 17:69-95. doi:10.1615/CritRevOncog.v17.i1.60
97. Li S, Brown MS, Goldstein JL. Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc Natl Acad Sci U S A (2010) 107:3441-6. doi:10.1073/pnas.0914798107
98. Yuan R, Kay A, Berg WJ, Lebwohl D. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol (2009) 2::45. doi:10.1186/1756-8722-2-45
99. Grimshaw KM, Hunter LJ, Yap TA, Heaton SP, Walton MI, Woodhead SJ, et al. AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth. Mol Cancer Ther (2010) 9:1100-10. doi:10.1158/1535-7163.MCT-09-0986
100. Bussenius J, Anand NK, Blazey CM, Bowles OJ, Bannen LC, Chan DS, et al. Design and evaluation of a series of pyrazolopyrimidines as p70S6K inhibitors. Bioorg Med Chem Lett (2012) 22:2283-6. doi:10.1016/j.bmcl.2012.01.105
101. Bilanges B, Vanhaesebroeck B. A new tool to dissect the function of p70 S6 kinase. Biochem J (2010) 431e1-3. doi:10.1042/BJ20101445
102. Pearce LR, Alton GR, Richter DT, Kath JC, Lingardo L, Chapman J, et al. Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). Biochem J (2010) 431:245-55.
103. Sunami T, Byrne N, Diehl RE, Funabashi K, Hall DL, Ikuta M, et al. Structural basis of human p70 ribosomal S6 kinase-1 regulation by activation loop phosphorylation. J Biol Chem (2010) 285:4587-94. doi:10.1074/jbc.M109.040667
104. Akritopoulou-Zanze I, Hajduk PJ. Kinase-targeted libraries: the design and synthesis of novel, potent, and selective kinase inhibitors. Drug Discov Today (2009) 14:291-7. doi:10.1016/j.drudis.2008.12.002
105. Wendt MD. Discovery of ABT-263, a Bcl-family protein inhibitor: observations on targeting a large protein-protein interaction. Expert Opin Drug Discov (2008) 3:1123-43. doi:10.1517/17460441.3.9.1123
106. Clark RC, Lee SY, Searcey M, Boger DL. The isolation, total synthesis and structure elucidation of chlorofusin, a natural product inhibitor of the p53-mDM2 protein-protein interaction. Nat Prod Rep (2009) 26:465-77. doi:10.1039/b821676b
107. Zhao J, Du Y, Horton JR, Upadhyay AK, Lou B, Bai Y, et al. Discovery and structural characterization of a small molecule 14-3-3 protein-protein interaction inhibitor. Proc Natl Acad Sci U S A (2011) 108:16212-6. doi:10.1073/pnas.1100012108
108. Hu L, Magesh S, Chen L, Wang L, Lewis TA, Chen Y, et al. Discovery of a small-molecule inhibitor and cellular probe of Keap1-Nrf2 protein-protein interaction. Bioorg Med Chem Lett (2013) 23:3039-43. doi:10.1016/j.bmcl.2013.03.013
109. Picaud S, Da Costa D, Thanasopoulou A, Filippakopoulos P, Fish PV, Philpott M, et al. PFI-1-a highly selective protein interaction inhibitor targeting BET bromodomains. Cancer Res (2013) 73(11):3336-46. doi:10.1158/0008-5472.CAN-12-3292
110. Koes DR, Camacho CJ. PocketQuery: protein-protein interaction inhibitor starting points from protein-protein interaction structure. Nucleic Acids Res (2012) 40:W387-92. doi:10.1093/nar/gks336
111. Koes DR, Camacho CJ. Small-molecule inhibitor starting points learned from protein-protein interaction inhibitor structure. Bioinformatics (2012) 28:784-91. doi:10.1093/bioinformatics/btr717